|1.||Waring, Alan J: 2 articles (02/2012 - 12/2002)|
|2.||Doros, G: 2 articles (10/2010 - 10/2010)|
|3.||Allen, R: 2 articles (10/2010 - 10/2010)|
|4.||Shaffer, Thomas H: 2 articles (01/2010 - 12/2005)|
|5.||Moya, Fernando R: 2 articles (02/2009 - 04/2005)|
|6.||Segal, Robert: 2 articles (10/2006 - 04/2005)|
|7.||Lu, Karen W: 2 articles (11/2005 - 08/2005)|
|8.||Goerke, Jon: 2 articles (11/2005 - 08/2005)|
|9.||Taeusch, H William: 2 articles (11/2005 - 08/2005)|
|10.||Goerke, J: 2 articles (10/2001 - 08/2000)|
|1.||Newborn Respiratory Distress Syndrome
06/01/2005 - "A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome."
04/01/2008 - "Moreover, the data obtained were compared with those of commercially available Surfacten (Surfactant TA) which has been clinically used for neonatal respiratory distress syndrome (NRDS) in Japan. "
06/01/2005 - "To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). "
08/01/1998 - "The mixtures were prepared by adding serial dilutions of human meconium to various concentrations of Surfactant-TA (Surfacten) that had been used for the prevention and treatment of neonatal respiratory distress syndrome. "
06/01/1987 - "The SM-SAP-6 combinants had adsorption facility equivalent to natural lung surfactant, and to the surfactant extract preparations CLSE and surfactant-TA used in exogenous surfactant replacement therapy for the neonatal Respiratory Distress Syndrome (RDS). "
10/01/2006 - "Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, our data showed KL(4)-surfactant, unlike vehicle or beractant, blocked neutrophil influx into alveoli and suppressed lung injury. "
10/01/2006 - "For the hyperoxic injury model, mice exposed to 80% O(2) for 6 days received an intranasal bolus of vehicle, beractant, or KL(4)-surfactant on days 3, 4, 5, and 6 of the exposure, and lungs were evaluated on day 7. Mice in the LPS-induced lung injury model received an intratracheal bolus of LPS followed by an intranasal bolus of KL(4)-surfactant or control at 1, 3, and 19 hr post-LPS challenge, and lungs were evaluated after 24 hr. To explore the mechanisms of protection, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was evaluated. "
11/01/2005 - "We treated rats with lavage lung injury with a commercial lung surfactant extract derived from bovine lung (Survanta) with or without addition of PEG. "
08/01/2005 - "After lung injury by instillation of meconium, they were treated with Survanta, Survanta with HA, or control mixtures. "
06/01/1993 - "Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury."
|3.||Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
01/01/1994 - "We report two cases of adult respiratory distress syndrome (ARDS) treated successfully with repeated doses of a bovine natural surfactant (Survanta). "
02/22/2012 - "We investigated a model of acute respiratory distress syndrome in which the serum protein albumin adsorbs to an air-liquid interface and prevents the thermodynamically preferable adsorption of the clinical lung surfactant Survanta by inducing steric and electrostatic energy barriers analogous to those that prevent colloidal aggregation. "
10/15/2001 - "To find whether this approach is effective in lung injuries that more closely resemble adult respiratory distress syndrome (ARDS), we have compared the use of Survanta with Survanta + PEG in two additional models of lung injury caused by either lipopolysaccharide (LPS) or HCl in adult rats. "
|4.||Hyaline Membrane Disease
04/01/2002 - "We tested the hypothesis that the initial functional residual capacity (FRC) of preterm infants with hyaline membrane disease (HMD) could predict the response to surfactant replacement (Survanta, 4 mL/kg/dose), with a better initial FRC being correlated with a greater improvement in PaO2, a/A PO2 ratio, and FRC. "
06/01/1985 - "As a prelude to clinical trials with a bovine surfactant (surfactant TA), in human infants with hyaline membrane disease, pulmonary and hemodynamic changes following its instillation in premature baboons were investigated. "
03/01/2001 - "Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease."
12/01/1989 - "We conducted a clinical trial to assess whether surfactant-TA given within the first six hours of life could improve oxygenation and reduce the ventilatory support in premature infants with hyaline membrane disease (HMD) during the first 24 hours of life. "
02/01/1988 - "Because the issue of optimal time for artificial surfactant therapy for hyaline membrane disease has not been established, the effects of treatment with a reconstituted bovine surfactant (surfactant TA) were compared at two time periods in a hyaline membrane disease model in a premature baboon. "
|5.||Lung Diseases (Lung Disease)
12/01/1994 - "In our recent prospective randomized trial, prophylactic use of Surfactant-TA prevented the development of RDS completely, and thereby reduced the incidence of chronic lung disease (odds ratio, 0.08 (92% reduction); p = 0.016). "
07/01/1994 - "We conclude that (1) the need for four doses of Survanta (administered as per protocol) was an early marker for this postsurfactant slump and (2) bronchopulmonary dysplasia at 36 weeks' postconceptional age was a better discriminator of chronic lung disease in this low-birth-weight group."
10/01/2013 - "No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively. "
05/01/1999 - "The long-term outcome as judged by the combined incidence of death or chronic lung disease was not different in the two groups (18.6% Exosurf vs. 15.2% Survanta; P > 0.05). "
10/01/1997 - "Ventilatory settings were increased, as needed, until the following maximum settings were reached: FIO2 of 1.0; peak inspiratory pressure of 40 cm H2O; and intermittent mandatory ventilation of 60 breaths/min. After 2 hrs of conventional ventilation or demonstration of clinically important lung disease by failure to maintain desired blood gases on the maximum ventilatory settings, 4 mL/kg of beractant was given intratracheally. "
|2.||Surface-Active Agents (Surfactants)
|4.||Exosurf (Exosurf Neonatal)
|5.||poractant alfa (Curosurf)
|6.||bovine surfactant preparation SF-RI 1
|10.||Silicon Dioxide (Sand)
|2.||Extracorporeal Membrane Oxygenation (ECMO)
|3.||Mechanical Ventilators (Ventilator)
|5.||Investigational Therapies (Experimental Therapy)